World leaders call for action to reduce TB deaths among HIV-positive people

For the first time ever, heads of governments, public health and business leaders, heads of UN agencies and activists came together at UN Headquarters today to confront a threat to global health that could undermine investments in life-saving drug treatment for people living with HIV.

Tuberculosis (TB) is every year taking the lives of nearly a quarter of million people living with HIV. It is the number one cause of death among people living with HIV in Africa. Worldwide it is a leading cause of death in this population.

WHO, the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the United Nations Children's Fund (UNICEF) recently announced that some 3 million people are now receiving life-saving antiretroviral treatment, but TB, especially drug-resistant forms of the disease, threatens to hinder this progress. Because HIV weakens the immune system, people living with HIV are up to 50 times more likely to develop TB in their lifetimes than people who are HIV negative. Without proper treatment with anti-TB drugs, the majority of people living with HIV die within two to three months of becoming sick with TB.

The leaders spelt out specific measures, recommended by WHO and needed to prevent deaths from HIV/TB. People living with HIV must be screened regularly for TB. Those who are sick with TB need effective TB treatment, and those without TB should receive preventive therapy with the drug isoniazid. These treatments are not expensive. A six-month course of TB treatment costs US$ 20, and a course of preventive drug therapy costs US$ 2. Simple measures to prevent the spread of TB among HIV-infected people, especially in health care settings, also need to be put in place.

In 2006, WHO reported that only 1% of the total estimated number of people infected with HIV worldwide were screened for TB. But some countries are making gains on detecting HIV among TB patients and providing life-saving treatments for both diseases.

Kenya, Malawi and Rwanda, for example, more than doubled the proportion of TB patients tested for HIV infection and treated appropriately between 2004 and 2007, according to national government data. In Kenya, the percentage of TB patients tested for HIV rose from 19% to 70%, and in Malawi the increase was from 25% to 83%. In Rwanda, in 2004, TB services were not testing any patients for HIV; in 2007, they tested 89%.

Today's HIV/TB Global Leaders Forum was convened by the UN Secretary-General's Special Envoy to Stop TB, Dr Jorge Sampaio, and was endorsed by the UN Secretary-General Ban Ki-moon. The forum was opened by the Secretary-General and Mr Srgjan Kerim, President of the UN General Assembly.

The leaders pointed to HIV/TB as a major constraint to economic development, since most TB deaths are among adults of working age. Because it most often strikes society's most disadvantaged people, they said, the dual epidemic is a barrier to social justice and human rights. They also warned that HIV/TB could evolve as a threat to global health security, particularly in the light of emergence of virtually untreatable TB strains.

Dr Sampaio will report on the outcome of the forum to the UN High-Level Meeting on AIDS, which begins tomorrow. Today's forum was supported by UNAIDS, the World Bank, WHO, the Global Fund to Fight AIDS, Tuberculosis and Malaria and the Stop TB Partnership.

For more information contact:

Judith Mandelbaum-Schmid
Stop TB Partnership
Mobile: +41 79 254 6835
E-mail: [email protected]

Glenn Thomas
WHO TB Department
Mobile: +41 79 509 0677
E-mail: [email protected]

Patricia Leidl
WHO HIV Department
Mobile: +41 79 619 8525
E-mail: [email protected]

Jon Liden
Global Fund to Fight AIDS, Tuberculosis and Malaria
Mobile: +41 22 79 11723
E-mail: [email protected]

Mahesh Mahalingham
UNAIDS
Mobile: +41 79 892 3814
E-mail: [email protected]

Phil Hay
World Bank
Mobile: +1 202 409 2909
E-mail: [email protected]

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Affordability and supply remain critical to the success of long-lasting HIV drug